Kamal S. Saini, Executive Medical Director and Head of European Oncology Team at Fortrea, shared a post on LinkedIn:
“Presented by Nadine Tung at the 2025 San Antonio Breast Cancer Symposium, the OlympiaN study NCT05498155 reported a pathological complete response rate of 68–80% in patients with early-stage ER-low, HER2-negative, BRCA-mutated breast cancer treated with neoadjuvant olaparib ± durvalumab, highlighting the potential activity of PARP inhibition with or without immunotherapy in this biologically distinct subgroup.
More posts featuring Kamal S. Saini.